I.V. Keppra "approvable," quick response
This article was originally published in Pharmaceutical Approvals Monthly
UCB has responded to a recent "approvable" letter for an intravenous formulation of its antiepileptic Keppra (levetiracetam), the firm reports Feb. 3. FDA had requested "revised product labeling as well as some additional information regarding manufacturing to finalize its review," UCB says. The company hopes I.V. Keppra will be of use in "emergency seizure situations where oral medication is not an option." Keppra would be the first of the newer antiepileptics to be available intravenously, according to UCB. Also on Feb. 3, the formulation received a positive opinion from the European Medicines Agency...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."